Avadel Pharmaceuticals(us:AVDL)
10.11
-1.94%
Updated on 2024-12-23
Open:10.30
Close:10.11
High:10.45
Low:9.97
Pre Close:10.31
Volume:398880.00
Amount:4.04M
Turnover:0.41%
Shares:96.27M
MarketCap:973.30M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 173 | 73666529 | 76.57% | 47 | 45 | 58 |
| 2024-03-31 | 147 | 70147028 | 73.00% | 37 | 43 | 49 |
| 2023-12-31 | 119 | 56101181 | 62.46% | 21 | 34 | 35 |
| 2023-09-30 | 115 | 54378629 | 60.83% | 14 | 35 | 43 |
| 2023-06-30 | 118 | 52774546 | 59.08% | 26 | 34 | 41 |
| 2023-03-31 | 99 | 48429256 | 75.11% | 17 | 36 | 26 |
| 2022-12-31 | 89 | 33443552 | 53.19% | 14 | 25 | 30 |
| 2022-09-30 | 90 | 31398954 | 51.57% | 10 | 21 | 31 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Janus Henderson Group Plc | 12915160 | 13.44% | 1789830 | 16.09% |
| 2024-03-31 | Rtw Investments, Lp | 8798558 | 9.16% | 1850640 | 26.64% |
| 2024-03-31 | Polar Capital Holdings Plc | 6753672 | 7.03% | 1890 | 0.03% |
| 2024-03-31 | Gendell Jeffrey L | 5708118 | 5.94% | 92768 | 1.65% |
| 2024-03-31 | Vivo Capital, Llc | 3972099 | 4.13% | -124329 | -3.04% |
| 2024-03-31 | Braidwell Lp | 2668549 | 2.78% | 2668549 | |
| 2024-03-31 | Wealth Effects Llc | 2264226 | 2.36% | -152100 | -6.30% |
| 2024-03-31 | Adage Capital Partners Gp, L.L.C. | 1910983 | 1.99% | 1685983 | 749.33% |
| 2024-03-31 | Millennium Management Llc | 1812317 | 1.89% | 1607783 | 786.07% |
| 2024-03-31 | Citadel Advisors Llc | 1563890 | 1.63% | 950705 | 155.04% |
About
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
Address:10 Earlsfort Terrace
Website:http://www.avadel.com
Market Movers